09:48 AM EST - BELLUS Health Inc. : And Auven Therapeutics, a global private equity company focused on accelerated development of breakthrough therapeutic drugs, today announced the completion of the KIACTA™ (eprodisate) Phase 3 confirmatory study for the treatment of AA amyloidosis. Top-line results are expected to be announced in Q2 2016 after all remaining patients have completed final study visits, all queries have been resolved based on input from study sites and the database has been locked. BELLUS Health Inc.
shares T.BLU are trading down $0.02 at $1.07.
